Background. Epidemiological studies have raised awareness of the problem of undiagnosed kidney disease and suggest that early identification and treatment will reduce the global burden of patients requiring dialysis. However, there are insufficient data on how to identify subjects who are at risk for developing overt kidney disease in a human immunodeficiency virus (HIV) population.
Introduction
As patients infected with human immunodeficiency virus (HIV) live longer while receiving highly active antiretroviral therapy (HAART), kidney disease has emerged as a significant cause of morbidity and mortality. The incidence and prevalence of kidney disease is becoming increasingly common in the Asian HIV population, as is the case with the Western HIV population [1] [2] [3] [4] [5] . In general, the early detection of kidney disease provides the opportunity to implement strategies known to inhibit the progressive loss of kidney function [6] [7] [8] [9] . Thus, the identification of HIVinfected individuals at risk of developing kidney disease is an important first step in modifying the progressive course of kidney disease [10, 11] .
Much of the previous work has focused on the risk factors for prevalent kidney disease or the progression to end-stage renal disease in HIV-infected patients. These include older age, hypertension and diabetes mellitus (DM). In addition, lipoprotein concentration, low CD4 cell count, high HIV load and coinfection with hepatitis C virus (HCV) are likely to be identified as specific risk factors for the HIV-infected population [4, 5, 12] . Moreover, several antiretroviral agents including tenofovir disoproxil fumarate (TDF) may be associated with nephrotoxicity or increased rates of HTN and DM which may in turn increase the risk of kidney disease [13] [14] [15] . However, most studies have been cross-sectional in nature and risk factors for the development of kidney disease have not been studied prospectively in patients without any overt signs of kidney disease.
The aim of this longitudinal study was to identify risk factors associated with the new occurrence of overt kidney disease during a short period in contemporary HIV-infected patients without evidence of kidney disease at baseline. In addition, we examined the cumulative impact of such factors on the development of kidney disease.
Materials and methods

Study design
This was a prospective cohort study aiming to ascertain the relationship between baseline characteristics and the new onset of overt kidney disease after a follow-up period of 2 years. New-onset kidney disease was defined as the incidence of either a urinary albumin-to-creatinine ratio (ACR) >30 mg/g (the conventional cut-off value for microalbuminuria) or an estimated glomerular filtration rate (eGFR) falling <60 mL/min/1.73 m 2 , being persistent at least for 3 months. The study protocol was approved by the local Institutional Review Board (approval certificate no. 681-09-1-13) and was in accordance with the 1975 Declaration of Helsinki as revised in 1996. Informed consent was obtained from all patients prior to enrollment.
Study population
A total of 507 ambulatory HIV-infected patients with no pre-existing kidney disease at baseline were recruited at the time of routine outpatient HIV care in Tokyo Metropolitan Komagome Hospital and attended both a baseline examination in 2008 and a follow-up examination in 2010. Patients were followed for at least six visits per year over a 2-year period. Of these, 429 participants (400 men and 29 women) completed the 2-year follow-up study. Seventy-eight patients were censored due to death, dropout or incomplete data. The longitudinal data were considered in August 2010. The pre-existing kidney disease was defined as either eGFR <60 mL/min/1.73 m 2 or ACR !30 mg/g (hereafter defined as microalbuminuria) at baseline. Mean age was 44.2 AE 10.9 (range 20-81) years. Mean CD4 cell count was 416 AE 199 /lL and HIV-RNA level was undetectable (<50 copies/mL) in 395 patients (92.1%). Mean ACR and eGFR at baseline were 9.97 AE 6.24 mg/g and 88.9 AE 16.4 mL/min/1.73 m 2 . A total of 407 patients (94.9%) were currently on HAART with 244 (59.9%) having received TDF and 226 patients (52.7%) currently taking TDF. TDF-boosted protease inhibitors were given to 140 patients (32.6%). HAART type and doses of antiretroviral drugs were not changed in any patient during the follow-up period. The electronic medical charts of all patients in the cohort were reviewed to determine the potential cause of kidney disease and the presence of comorbidities such as hypertension, DM, hyperlipidemia and hepatic viral infection. Hypertension was defined as a systolic blood pressure !140 mmHg and/or a diastolic blood pressure !90 mmHg or the use of antihypertensive agents at baseline. DM was defined as a diagnosis of diabetes mellitus prior to baseline or the use of oral anti-diabetic agents or insulin at baseline. Hepatitis B virus (HBV) infection was defined as a positive HBV surface antigen test, while HCV infection was defined as a positive reactive HCV antibody test. Alcohol, the use of antihypertensive drugs such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers and use of illicit drugs was not fully assessed.
Measurements
Non-fasting blood and urine samples were collected randomly for analysis as part of a routine clinical visit. Serum creatinine (Cr) was measured using the enzyme assay (IATRO LQ CRE (A) II; Mitsubishi Chemical Medicine Corporation, Tokyo, Japan). The eGFR based on serum Cr was calculated using the formula constructed by the Japanese Society of Nephrology [eGFR (mL/min/1.73 m 2 ) ¼ 194 3 Serum Cr À1.094 3 Age À0.287 3 0.739 (if female)] [16] . Urinary albumin was measured by a turbidimetric immunoassay. Albuminuria was defined as ACR of !30 mg/g. The sustained abnormality in albumin excretion and eGFR was confirmed by at least two consecutive measurements conducted 3 months apart. CD4 cell counts in HIV-infected patients were determined using a specific monoclonal antibody and flow cytometry analysis. HIV-RNA level was measured using the Roche Amplicor HIV Monitor assay based on the reverse transcription-polymerase chain reaction (Roche Molecular Systems, Tokyo, Japan; lower detection limit was 50 copies/mL). Anti-HCV antibodies were measured using a third-generation enzyme immunoassay test (Abbott laboratories, Tokyo, Japan). Other laboratory variables were measured using standard methods as described previously [2, 17] .
Statistical analyses
All data are expressed as the mean AE SD. Common logarithmic transformation was applied to HIV RNA levels and CD4 cell counts to normalize the skewed distribution. Demographic characteristics and laboratory values of patients with and without microalbuminuria or renal dysfunction were compared using Fisher's exact probability test for categorical variables and Mann-Whitney U-test for continuous variables, respectively. Associations between the incident microalbuminuria or renal dysfunction and clinical variables at baseline were estimated using Cox proportional hazards regression analysis. The adjustment variables considered were those that differed at baseline between patients who subsequently did or did not develop kidney disease and those that were hypothesized to be possible confounders on the basis of previous literature [4] [5] [6] . As the first step in building multivariate models, the variables were individually evaluated using univariate regression models. They were used to examine age, gender, body mass index (BMI), current smoking habit, coexistence of hypertension, DM, HCV antibody, HIV RNA level, CD4 cell count, ACR, eGFR, haemoglobin (Hb), serum cholesterol, serum triglycerides and use of TDF-boosted protease inhibitors. Baseline eGFR was divided into two groups such as 60-89 and !90 mL/min/1.73 m 2 . Subclinical levels of baseline ACR were also categorized into three groups such as 0-9, 10-19 and 20-29 mg/g. Subsequently, multivariate models included covariates determined to be statistically important on the basis of associations with new kidney disease in the univariate analyses (P 0.10 for entry criteria) and the hazard ratio (HR) and 95% confidence interval (CI) were obtained. The investigators then reviewed the model and covariates to confirm clinical relevance. A second analysis was conducted by using multivariate Cox models to examine the number of risk factors present at baseline (risk scores) and the HRs of developing kidney disease. In this analysis, age was divided into two groups at the age of 50 years, according to the data on prevalence of CKD in the Japanese general population [18] and the mean value of patients with kidney disease after the follow-up. Results were adjusted for gender, log HIV RNA level and log CD4 cell count. All statistical analyses were conducted using JMP 8.0 (SAS Institute, Cary, NC). P-values <0.05 were considered to be statistically significant.
Results
Baseline characteristics stratified by kidney disease after the 2-year follow-up period ]. In addition, four individuals (0.93%) developed both microalbuminuria and renal dysfunction. Table 1 depicts the data of cases that did or did not develop kidney disease. Age, baseline ACR and the presence of DM or HCV coinfection were different between cases that developed microalbuminuria and those who did not. In addition, age, BMI, baseline ACR, baseline eGFR and the proportion of TDF-boosted protease inhibitors use and TDF use were different between cases that developed renal dysfunction and those who did not. Indices of HIV infection status such as HIV RNA level and CD4 cell count, serum albumin and lipid levels, Hb concentration, coexistence of hypertension and HBV infection and smoking habit were comparable between cases that developed evidence of kidney disease and those who did not.
Baseline predictors of the development of microalbuminuria after the 2-year follow-up period Table 2 shows the predictors of the development of microalbuminuria that were adjusted for multiple covariates. Baseline predictors of the development of microalbuminuria included the following factors (HR with 95% CI): age, 1.03 (1.00-1.07); coexisting diabetes, 4.41 (1.04-16.1); HCV coinfection, 7.91 (1.56-33.2); ACR 10-19 mg/g, 11.5 (3.51-52.6) and ACR 20-29 mg/g, 49.0 (13.9-236). Baseline predictors of the development of renal dysfunction after the 2-year follow-up period 
4).
Relationship between the number of risk factors at baseline and the risk of developing kidney disease Based on the data shown in Tables 2 and 3 , selected risk factors for the development of albuminuria included the presence of (i) age !50 years, (ii) DM (1), (iii) HCV infection (1) and (iv) ACR 10-19 mg/g or ACR 20-29 mg/g, while those for renal dysfunction included baseline (i) age !50 years, (ii) eGFR 60-89 mL/min/1.73 m 2 , (iii) ACR 10-19 mg/g or ACR 20-29 mg/g and (iv) use of TDF-boosted protease inhibitors. 'Score 1' was assigned to each risk factor except ACR 20-29 mg/g, to which 'score 2' was assigned. The maximum score is a total of 5 points when four risk factors are applicable to an HIVinfected patient. As shown in Table 4 , the risk for new kidney disease increased~3-fold per 1-U increase in the number of risk scores.
Discussion
The results of this study highlight several risk factors for the development of overt kidney disease in HIV-infected individuals in the contemporary era of effective antiretroviral therapy. These results are novel because much of the previous work focused on the risk factors associated with prevalent kidney disease, whereas we have attempted to identify risk factors that lead to the near-future kidney disease. The first key finding of this study is that increased urinary albumin levels within the normal range are independently associated with subsequent development of microalbuminuria and renal dysfunction in HIV-infected patients. The second key finding is that the presence of several concurrent risk factors is likely to have a great synergistic impact upon the future development of kidney disease.
Although albumin excretion has not yet been fully established as evidence of a poorer renal outcome in individuals with HIV infection, our findings clarified that the middle to high levels within the normal range of albuminuria carries the strong risk for the development of kidney disease during the short period. Microalbuminuria, defined as the pathological excretion of albumin at levels (30-300 mg/ g) below the detection threshold of conventional urinary dipstick analysis, is a key marker of the development and progression of renal disease such as diabetic nephropathy [19] . In general, increased urinary albumin levels within the normal range were associated with subsequent development of albuminuria or renal impairment in patients with type 2 diabetes [20] . Furthermore, low-grade albuminuria (10.2-29.9 mg/g) was associated with increased CKD prevalence among a general Asian adult population (n ¼ 6915) who received routine health status checkups [21] . Szczech et al. [22, 23] demonstrated a strong and independent association of HIV infection per se with albumin excretion and a beneficial association of HAART initiation with a decrease in albuminuria over time, thereby suggesting that HIV may well infect and disrupt glomerular cells. In addition, it may be hypothesized that dysfunction of endothelial cells is involved in the emergence of microalbuminuria. Endothelial cell dysfunction is a harbinger to vascular damage and is commonly found in cardiovascular and kidney disease [24, 25] . Recently, Choi et al. [26, 27] demonstrated that the level of albuminuria is strongly associated with the risk of cardiovascular disease, heart failure and 5-year all-cause mortality in the samples of HIVinfected individuals included in the US study-the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Study. Therefore, our current data underscores the clinical relevance of monitoring low-grade albuminuria within the normal range (<30 mg/g) as it likely identifies HIV-infected patients at heightened risk for future cardiovascular disease and death as well as future kidney disease. Our study showed that HCV coinfection was a likely predictor of incident microalbuminuria in the HIV-infected population. Liangpunsakul et al. [28] conducted a nested case-control study to examine the relationship between non-diabetic subjects with HCV coinfection and microalbuminuria by using database from the Third National Health and Nutrition Examination Survey (NHANES III) that was conducted in the USA from 1988 through 1994. After controlling for relevant covariates, they showed that HCV infection was independently associated with microalbuminuria in subjects without diabetes, insulin resistance or the metabolic syndrome. In addition, using the NHANES III database, Tsui et al. [29] confirmed an independent association between microalbuminuria and HCV seropositivity among adults who were stratified by age. We do not offer mechanic clues as to why HIV-infected patients with HCV coinfection exhibit a higher prevalence of microalbuminuria as renal biopsy was not performed in any patients, but the latent existence of glomerular disease such as membranoproliferative or membranous glomerulonephritis associated with HCV infection might be involved [30] .
Our study showed that HIV-infected patients with a mildly reduced GFR at baseline (60-89 mL/min/1.73 m 2 ) had an increased risk of developing renal dysfunction during the 2-year follow-up period. Experimental models of acquired nephron loss indicate that nephron loss (5/6 nephrectomy) alone can initiate a cycle of progressive glomerular injury largely mediated through glomerular . Italic values indicate that the associations of variables with renal dysfunction are statistically significant (P < 0.05). Variables with P-value >0.10 in univariate analysis are not included in multivariate analysis. PI, protease inhibitor. Microalbuminuria is defined as urinaryACR !30 mg/g. Renal dysfunction is defined as eGFR <60 mL/min/1.73 m 2 . b Risk factors include (i) age !50, (ii) diabetes mellitus, (iii) hepatitis C infection and (iv) ACR 10-19 mg/g or ACR 20-29 mg/g for albuminuria and (i) age !50, (ii) baseline eGFR <90, (iii) ACR 10-19 mg/g or ACR 20-29 mg/g and (iv) use of tenofovir-boosted protease inhibitors for renal dysfunction. 'Score 1' is assigned to each risk factor except ACR 20-29 mg/g, to which 'score 2' is assigned. The maximum score is a total of 5 points when four risk factors are applicable to an HIV-infected patient.
hypertension and hyperfiltration [31] . In most forms of human kidney disease, focal nephron loss initially occurs as a result of primary renal disease or exposure to nephrotoxic agents, and subsequent hemodynamic adaptations in remaining glomeruli contribute to further nephron loss over time. A study found an increased risk of developing kidney disease associated with an eGFR of 60-90 mL/min/1.73 m 2 in a community-based general population without evidence of kidney disease at baseline (odds ratio, 3.01 versus eGFR !120 mL/min/1.73 m 2 ) [32] . These findings may suggest that HIV-infected individuals with a mild subclinical decrease in eGFR should be considered to be at risk for the near-term development of kidney dysfunction.
Our study showed that HIV-infected patients receiving TDF-boosted protease inhibitors were at greater risk for a future decline in eGFR. There are conflicts regarding chronic renal safety of TDF because TDF-associated renal disease might be dependent on the patients' conditions including treatment-experience and baseline renal illness [4, 5] . However, several prospective studies have recently shown decreases in eGFR among patients on TDF-boosted protease inhibitors. In particular, Goicoechea et al. clearly showed that TDF-boosted protease inhibitor regimen was associated with a 7-10 mL/min greater decrease in GFR over 48 weeks, compared with a TDF-non-nucleoside reverse-transcriptase inhibitor or non-TDF-containing regimen. This suggests that boosted protease inhibitors may increase TDF nephrotoxic potential by competing for the same tubular transporters, thus impairing its tubular secretion [33] . Thus, our result may alert clinicians to have more interest in the impact of TDF-boosted protease inhibitor regimen rather than that of overall regimens.
This may be the first study to address an association between the number of risk factors present and the risk of developing kidney disease in an HIV-infected population. Clinical experience suggests that the presence of several concurrent risk factors in individuals might have cumulative effects on kidney disease in the HIV-infected individuals. Risk scoring has recently been emphasized as a practical tool to help stratify individuals at increased risk of prevalent and incident kidney disease in the general population [34, 35] . However, there have been no studies showing the combined effect of several risk factors for the future development of kidney disease specifically in an HIV-infected population. As HIV-infected patients with multiple risk factors including (i) age, (ii) DM, (iii) HCV, (iv) low-grade albuminuria, (v) a mild decrease in eGFR and (vi) use of TDF-boosted protease inhibitors are at much greater risk for the development of overt kidney disease, the increased frequency of monitoring and more intensive management of such risk factors is warranted.
This study has several limitations. First, it has not yet been validated that the eGFR based on serum Cr-based formula is applicable to an HIV-infected population. However, Barraclough et al. [36] recently performed a comparative analysis of all currently available methods of assessing kidney function in HIV-infected adults including Cr-based estimation equations, 24-h urine Cr clearance, estimated cystatin C GFR with nuclear GFR using 99m TcPentetate used as the gold standard. They demonstrated that relative accuracy to within 30% of the isotopic GFR measurement was greater for the Modification of Diet in Renal Disease formula than for all other methods. Second, the study sample was mostly limited to patients receiving antiretroviral therapy with good control of HIV infection, as we attempted to know risk factors of kidney disease in the contemporary era of effective HAART. This may explain our finding that neither the HIV RNA level nor CD4 count are significant risk factors for the onset of kidney disease. Finally, our results are based on a relatively short period of follow-up as we believe that short-term risk estimates may serve to motivate patients and physicians to pay attention to their kidney disease. This study did not show that conventional risk factors for kidney disease such as hypertension, dyslipidemia and smoking are involved in the development of kidney disease. Further study will be needed to determine if these factors are relevant to longterm outcome.
In conclusion, we have demonstrated several predictors for the development of kidney disease in HIV-infected patients during the 2-year follow-up period. In particular, patients with multiple predictors including low-grade albumin excretion should be carefully monitored, as it may have a great impact on the subsequent development of both microalbuminuria and renal dysfunction. Whether early modification of subclinical albuminuria can prevent or delay the progression of kidney disease and can be validated in independent samples warrants further investigation.
